Thrombopoietin R產品信息
英文名稱：Thrombopoietin receptor
中文名稱：血小板生成素受體
靶點別稱：MPL,C-MPL,CD110,MPLV,THCYT2,TPOR
物種：Human
標簽：His Tag
屬性：Protein
標記：Unconjugated
表達區(qū)間及表達系統(tǒng)（Source）
Human Thrombopoietin R, His Tag (THR-H52H7) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Trp 491 (Accession # P40238-1 ).
Predicted N-terminus: Gln 26
蛋白結構（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 54.4 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
Thrombopoietin R分子背景
Thrombopoietin R, also known as TPO-R, is expressed predominantly on the surface of MKs, platelets, hemangioblasts, and hematopoietic stem cells (HSCs). Binding of TPO to the megakaryocyte TPO-R leads to different effects: prevention of megakaryocyte apoptosis; increased megakaryocyte number, size, and ploidy; increasing rate of megakaryocyte maturation; and internalization of the TPO/TPO-R complex. Thrombopoietin R involved in multiple signal transduction pathways, such as JAK, STAT, and MAP kinase.
關鍵字： Thrombopoietin R;Thrombopoietin R蛋白;血小板生成素受體;Thrombopoietin;Thrombopoietin受體;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。